Advertisement
The Body: The Complete HIV/AIDS Resource
Sign up for free e-mail updates!The Body en Espanol
  • E-mail E-Mail
  • Printer Friendly Printable Single-Page
  • Glossary Glossary
  • Bookmark and Share Share
AIDS Project Los Angeles

Limited T-20 Compassionate Use Program Launches in October

September/October 2002


This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Individuals with HIV who are in need of a salvage therapy and who meet certain criteria may be able to access T-20, also known as Fuzeon, through a compassionate use program expected to begin in October.

T-20, a member of a new class of drugs called fusion inhibitors, is administered by injection twice a day. FDA approval of the drug is expected soon.

Only 600 slots in the program are available. Individuals enrolling in the program must be 6 years old or older, have a viral load greater than 10,000 copies and a CD4 count of less than 100 cells/mm3 while on highly active antiretroviral therapy. Individuals must also "be limited by the currently commercial available antiretroviral agents as per the judgment of the investigator," according to a letter announcing the program.

Individuals interested in the program should consult their physicians.

Advertisement

Back to the September/October 2002 issue of Positive Living.


This article has been reprinted at The Body with the permission of AIDS Project Los Angeles (APLA).


This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.


This article was provided by AIDS Project Los Angeles. It is a part of the publication Positive Living.
  • E-mail E-Mail
  • Printer Friendly Printable Single-Page
  • Glossary Glossary
  • Bookmark and Share Share

See Also
More on HIV Medications

 

Advertisement